SETDB1 modulates the TGFβ response in Duchenne muscular dystrophy myotubes.
Alice GranadosMaeva ZamperoniRoberta RaponeMaryline MoulinEkaterina BoyarchukCostas BouyioukosLaurence Del MaestroVéronique JoliotElisa NegroniMyriame MohamedSandra PiquetAnne BigotFabien Le GrandSonia AlbiniSlimane Ait-Si-AliPublished in: Science advances (2024)
Overactivation of the transforming growth factor-β (TGFβ) signaling in Duchenne muscular dystrophy (DMD) is a major hallmark of disease progression, leading to fibrosis and muscle dysfunction. Here, we investigated the role of SETDB1 (SET domain, bifurcated 1), a histone lysine methyltransferase involved in muscle differentiation. Our data show that, following TGFβ induction, SETDB1 accumulates in the nuclei of healthy myotubes while being already present in the nuclei of DMD myotubes where TGFβ signaling is constitutively activated. Transcriptomics revealed that depletion of SETDB1 in DMD myotubes leads to down-regulation of TGFβ target genes coding for secreted factors involved in extracellular matrix remodeling and inflammation. Consequently, SETDB1 silencing in DMD myotubes abrogates the deleterious effect of their secretome on myoblast differentiation by impairing myoblast pro-fibrotic response. Our findings indicate that SETDB1 potentiates the TGFβ-driven fibrotic response in DMD muscles, providing an additional axis for therapeutic intervention.
Keyphrases
- duchenne muscular dystrophy
- transforming growth factor
- epithelial mesenchymal transition
- extracellular matrix
- muscular dystrophy
- oxidative stress
- skeletal muscle
- randomized controlled trial
- single cell
- dna methylation
- systemic sclerosis
- idiopathic pulmonary fibrosis
- machine learning
- big data
- mass spectrometry
- artificial intelligence
- single molecule
- atomic force microscopy
- anti inflammatory